Zidovudine was first synthesized in 1964. After continuous screening by scientists, the compound was developed and marketed by Wellcome Company in the UK, and was approved by FDA in March 1987. It was first used for the prevention and treatment of HIV/AIDS with the trade name of "Li Tuowei". It was clinically used in nearly 100 countries in the 20th century and was listed in the British Pharmacopoeia 1998 edition. It is also the first of1987 ~ 17 AIDS drugs approved by FDA in 1999.
After the administrative protection of zidovudine capsules in China expired in February 20001.65438, Northeast Pharmaceutical General Factory obtained the new drug certificate and production approval issued by SFDA in August 2002, with the trade name of "Kedu".
As governments around the world give the green light to anti-AIDS drugs and strictly control the prices of such drugs, manufacturers will naturally not spend time and energy on a product with little profit margin. However, with the rapid increase of incidence in the world, especially in developing countries, the huge demand makes enterprises still interested in developing and paying attention to these varieties.
The main domestic manufacturers are Northeast Pharmaceutical General Factory, Shandong Phoenix Pharmaceutical Co., Ltd., Hangzhou Ke Ben Chemical Co., Ltd., Xiamen Mike Pharmaceutical Group and Anhui Baker Pharmaceutical Co., Ltd., among which Anhui Baker Pharmaceutical Co., Ltd. has internationally advanced chiral compound synthesis technology. Since 2002, it has successively put into production a number of anti-AIDS drugs, including zidovudine, lamivudine, stavudine and other raw materials.
Because the dosage of zidovudine is small, there are few domestic manufacturers. However, due to the strong demand for AIDS drugs, it is still in a state of insufficient supply and demand. Most manufacturers are out of stock and have placed orders in the second half of the year. There seems to be a considerable vacancy in this market.